EP3866851A4 - Exosome-targeting bispecific antibodies - Google Patents

Exosome-targeting bispecific antibodies Download PDF

Info

Publication number
EP3866851A4
EP3866851A4 EP19872880.0A EP19872880A EP3866851A4 EP 3866851 A4 EP3866851 A4 EP 3866851A4 EP 19872880 A EP19872880 A EP 19872880A EP 3866851 A4 EP3866851 A4 EP 3866851A4
Authority
EP
European Patent Office
Prior art keywords
exosome
bispecific antibodies
targeting bispecific
targeting
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19872880.0A
Other languages
German (de)
French (fr)
Other versions
EP3866851A1 (en
Inventor
Matthew K. Robinson
Michael John MORIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunome Inc
Original Assignee
Immunome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc filed Critical Immunome Inc
Publication of EP3866851A1 publication Critical patent/EP3866851A1/en
Publication of EP3866851A4 publication Critical patent/EP3866851A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EP19872880.0A 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies Pending EP3866851A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Publications (2)

Publication Number Publication Date
EP3866851A1 EP3866851A1 (en) 2021-08-25
EP3866851A4 true EP3866851A4 (en) 2022-11-02

Family

ID=70284767

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19872880.0A Pending EP3866851A4 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Country Status (12)

Country Link
US (1) US20210347895A1 (en)
EP (1) EP3866851A4 (en)
JP (1) JP2022512734A (en)
KR (1) KR20210091714A (en)
CN (1) CN113423425A (en)
AU (1) AU2019359877A1 (en)
BR (1) BR112021007469A2 (en)
CA (1) CA3116560A1 (en)
IL (1) IL282355A (en)
MX (1) MX2021004036A (en)
SG (1) SG11202103812RA (en)
WO (1) WO2020081786A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115149A1 (en) * 2018-10-02 2020-04-09 Immunome, Inc. Antibodies targeting epn1
CN114990129B (en) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 Preparation and application of mesenchymal stem cells expressing alpha PDL1: fc fusion protein
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136820A2 (en) * 2016-02-06 2017-08-10 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2017162890A1 (en) * 2016-03-25 2017-09-28 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
BR112017010324A2 (en) * 2014-11-20 2018-05-15 F. Hoffmann-La Roche Ag method for treating or slowing cancer progression in an individual, molecules, methods for enhancing immune function in an individual and for selecting a patient for treatment, kits, pharmaceutical composition and uses of a combination of one molecule
CN108235685A (en) * 2015-07-29 2018-06-29 诺华股份有限公司 The combination of PD-1 antagonists and EGFR inhibitor
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN108250302A (en) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 A kind of multifunctional protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136820A2 (en) * 2016-02-06 2017-08-10 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2017162890A1 (en) * 2016-03-25 2017-09-28 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
&#XF0B7; GENMAB: "Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma Company Announcement", 21 March 2016 (2016-03-21), XP055377957, Retrieved from the Internet <URL:https://www.globenewswire.com/news-release/2016/03/21/821840/0/en/Genmab-Announces-Studies-of-Daratumumab-in-Combination-with-Atezolizumab-in-a-Solid-Tumor-and-Multiple-Myeloma.html> [retrieved on 20170601] *
G. KO ET AL: "Selective high-level expression of epsin 3 in gastric parietal cells, where it is localized at endocytic sites of apical canaliculi", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 50, 29 November 2010 (2010-11-29), pages 21511 - 21516, XP055702752, ISSN: 0027-8424, DOI: 10.1073/pnas.1016390107 *
See also references of WO2020081786A1 *

Also Published As

Publication number Publication date
KR20210091714A (en) 2021-07-22
CN113423425A (en) 2021-09-21
BR112021007469A2 (en) 2021-08-10
SG11202103812RA (en) 2021-05-28
US20210347895A1 (en) 2021-11-11
CA3116560A1 (en) 2020-04-23
JP2022512734A (en) 2022-02-07
MX2021004036A (en) 2021-08-24
EP3866851A1 (en) 2021-08-25
WO2020081786A1 (en) 2020-04-23
AU2019359877A1 (en) 2021-05-20
IL282355A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
EP3903817A4 (en) Novel anti-ccr8 antibody
IL279235A (en) Dll3-cd3 bispecific antibodies
EP3487888A4 (en) Bispecific anti-her2 antibody
EP3850007A4 (en) Engineered bispecific proteins
EP3986936A4 (en) Anti-tigit antibodies
EP3507307A4 (en) Bispecific antibodies
EP3941944A4 (en) Claudin-6 bispecific antibodies
EP3784699A4 (en) Optimized anti-tl1a antibodies
EP3763743A4 (en) Bispecific antibody
EP3746120A4 (en) Anti-pd-1 antibodies
EP3883970A4 (en) An anti-b7-h3 antibody
EP3752536A4 (en) Anti-her2 antibodies
AU2018297058A1 (en) Bispecific anti PD1-anti TIM3 antibodies
EP3831851A4 (en) Anti-btla antibody
AU2019361253A1 (en) Anti-synuclein antibodies
EP3626745A4 (en) Recombinant bispecific antibody
EP3768724A4 (en) Novel anti-pd-1 antibodies
IL282355A (en) Exosome-targeting bispecific antibodies
EP3693013A4 (en) Bispecific antibody
EP3986462A4 (en) Anti-tim-3 antibodies
EP3852779A4 (en) Anti-klrg1 antibodies
IL286757A (en) Bispecific antibodies
IL286918A (en) Bispecific antibody
EP3901173A4 (en) Bispecific protein
EP3862366A4 (en) Cancer-stem-cell-specific antibody

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/32 20060101ALI20220624BHEP

Ipc: C07K 16/46 20060101ALI20220624BHEP

Ipc: C07K 16/30 20060101ALI20220624BHEP

Ipc: C07K 16/28 20060101ALI20220624BHEP

Ipc: A61K 39/395 20060101AFI20220624BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20221004

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/32 20060101ALI20220927BHEP

Ipc: C07K 16/46 20060101ALI20220927BHEP

Ipc: C07K 16/30 20060101ALI20220927BHEP

Ipc: C07K 16/28 20060101ALI20220927BHEP

Ipc: A61K 39/395 20060101AFI20220927BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601